Outcomes of patients with multiple myeloma harboring chromosome 1q gain/amplification in the era of modern therapy

• Published in: Annals of hematology Vol. 101; no. 2; pp. 369 - 378
• Main Authors: Hu, Xiao, Wu, Cherng-Horng, Cowan, Janet M., Comenzo, Raymond L., Varga, Cindy
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.02.2022; Springer Nature B.V
• Subjects: Aged; Chromosome Duplication; Chromosomes, Human, Pair 1; Disease Management; Female; Hematology; Humans; Immunotherapy; Male; Medical prognosis; Medicine; Medicine & Public Health; Middle Aged; Monoclonal antibodies; Multiple myeloma; Multiple Myeloma - epidemiology; Multiple Myeloma - genetics; Multiple Myeloma - therapy; Oncology; Original Article; Retrospective Studies; Survival Analysis; Targeted cancer therapy; Prognosis; Lenalidomide; Chromosome 1q gain/amplification; Daratumumab; Multiple myeloma
• ISSN: 0939-5555; 1432-0584
• DOI: 10.1007/s00277-021-04704-8

Chromosome 1q gain/amplification (1q +) has been reported to be associated with inferior outcomes in multiple myeloma (MM) patients. Big therapeutic advances have shifted the treatment landscape by introducing monoclonal antibodies. There is a relative lack of data on outcomes in patients harboring this alteration in the era of monoclonal antibodies. Baseline characteristics and therapy-related data from newly diagnosed MM patients harboring 1q + detected by fluorescence in situ hybridization (FISH) were collected in a single institution. Among 34 identified subjects, the presence of elevated LDH was found to be associated with shorter overall survival (OS), and increased bone marrow plasma cell percentage (≥ 60%) was associated with worse progression-free survival (PFS). 1q + copy number more than three was associated with both shorter OS and PFS. Additionally, the administration of lenalidomide was associated with superior OS. The use of autologous stem cell transplantation, bortezomib, or daratumumab, was found to have no prognostic benefits in our sample. Lenalidomide may be an optimal therapeutic choice for this population, and future larger studies are warranted to confirm this benefit and further investigate the role of monoclonal antibodies in this subpopulation.